SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to a mix of earnings results and news of Michael Burry's significant short position against the stock, sparking debates about valuation and future growth potential. Community discussions revolve around whether the company is overvalued, with some defending its AI capabilities and government contracts, while others point to its high P/E ratio and the potential impact of Burry's bet.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions about its recent earnings and the impact of COVID-era data on trial results for PMO therapies; while some express concern over missed statistical significance, others highlight the revenue beat and potential for Elevidys to replace older treatments. The community is debating the likelihood of FDA action on PMO drugs and the company's overall valuation in light of recent events, with some suggesting a buyout opportunity.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending amid community discussion around its recent price movements and potential. Some traders highlight its relative strength as Bitcoin and other cryptos decline, while others remain skeptical, citing its past performance. Discussions include its technology, future potential, and the impact of upcoming announcements.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

HIMS is trending amid mixed sentiment heading into earnings, with discussions around a potential deal with Novo Nordisk for weight-loss drugs like Wegovy. The community is closely watching subscriber growth and margin expansion, while analysts debate the impact of increased competition and past concerns regarding GLP-1s. Some traders are betting on a post-earnings squeeze, while others point to technical indicators suggesting further downside.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending due to a post-earnings selloff, with the community debating whether the drop is an overreaction or a sign of deeper issues related to AI spending and future profitability. Sentiment is mixed, ranging from calls to buy the dip to concerns about technicals and potential further declines. Some traders are pointing to historical patterns and oversold conditions as potential catalysts for a bounce.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending amid a broader crypto selloff, with the community debating potential bottom prices and the influence of external factors like government shutdowns and the TradFi market. Traders are closely watching technical indicators, while some express frustration with price predictions from crypto analysts. Liquidations and market manipulation remain key concerns.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

TSLA is trending as investors discuss the upcoming shareholder vote on Elon Musk's substantial pay package and its potential impact on his commitment to the company. Concerns raised by major investors, including Norway's wealth fund, about governance and potential dilution are fueling debate.  Community members are weighing the implications of approval versus rejection on market confidence and Tesla's long-term vision, amidst discussions of sales figures and ambitious growth plans.

Grab Holdings Ltd. engages in the provision of millions of people each day to access its driver- and merchant-partners to order food or groceries, send packages, hail a ride or taxi, pay for online purchases or access services such as lending, insurance, wealth management and telemedicine, all through a single “everyday everything” app. The firm operates in food deliveries and mobility and by TPV in the e-wallets segment of financial services in Southeast Asia. It operates across the deliveries, mobility and digital financial services sectors in eight countries namely: Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam. The company was founded by Anthony Tan Ping Yeow and Tan Hooi Ling in 2012 and is headquartered in Singapore.

Grab Holdings Limited - Ordinary Shares - Class A

Grab Holdings Limited

Grab ($GRAB) is trending due to increased retail investor buzz after the company raised its earnings forecast.  The community is discussing its impressive On-Demand GMV growth and raised full-year revenue guidance.  Some see Grab as an emerging fintech opportunity and a dominant player in the Southeast Asian market.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as traders discuss its potential as 'the better Bitcoin' due to its privacy features and limited supply, with some community members speculating about a short squeeze and a rapid price surge to $1,000.  The conversation also highlights ZEC as a hedge against Bitcoin's volatility, with some suggesting a rotation from BTC into ZEC.  Mentions of its upcoming anniversary and bullish technical indicators add to the current hype.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid concerns of an AI bubble burst and potential market correction, fueled by overnight futures drops. Community chatter highlights skepticism towards the sustainability of the tech-led rally, with some bracing for a significant pullback. Traders are closely watching key support levels and debating whether this is a buying opportunity or the start of a deeper downturn.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue?

Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?

BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Teladoc Health Expands Clarity Platform With Workplace Safety Tool

TDOC enhances its Clarity platform with an AI-driven tool to help hospitals combat rising workplace violence incidents.

Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics

Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.

5 Small Drug Stocks to Buy as the Industry Shows Some Recovery

Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.

Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates

Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.

Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of +800.00% and +37.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?

Ironwood Pharmaceuticals shares dropped 14.6% on Wednesday after the company reported a steep revenue miss in the first quarter, attributing the shortfall to a timing shift in rebates related to its gastrointestinal drug Linzess.&nbsp;The company maintained its full-year guidance and noted progress on a strategic review and pipeline development.The stock closed at $0.79, down $0.13 on Wednesday, and remained flat in after-hours trading.Ironwood posted Q1 2025 revenue of $41.1 million, down from $74.9 million a year earlier and well below the $56.7 million consensus estimate.&nbsp;GAAP net loss widened to $37.4 million, or $0.23 per share, compared to $0.03 per share in the year-ago quarter. Non-GAAP net loss came in at $0.14 per share.The company attributed the revenue decline to a change in gross-to-net rebate reserve estimates from partner AbbVie, which impacted the phasing of&nbsp;Linzess's U.S. net sales but is not expected to affect full-year results.&nbsp;Collaboration revenue related to Linzess dropped 46% year-over-year to $38.8 million.Ironwood reaffirmed its 2025 U.S. Linzess net sales forecast of $800 million to $850 million and raised its adjusted EBITDA outlook to over $105 million.&nbsp;Prescription demand for Linzess rose 8% year-over-year in Q1, in line with expectations. The company ended the quarter with $108.5 million in cash and cash equivalents, up from $88.6 million at year-end.Management said it will focus on maximizing shareholder value, including through a planned confirmatory Phase 3 trial for apraglutide and an ongoing strategic alternatives review with Goldman Sachs.Analyst sentiment soured as Wells Fargo downgraded the company to 'Equalweight' from 'Overweight,' slashing its price target from $7 to $1, according to Koyfin.Similarly, Jefferies downgraded Ironwood to 'Hold' from 'Buy,' lowering its target from $8 to $0.70, Koyfin data said.&nbsp;On Stocktwits, sentiment was ‘bearish’ amid ‘normal’ message volume.&nbsp;Some users criticized the lack of an earnings call, with one remarking that the company simply dropped the earnings release without discussion — a departure from its decade-long tradition — and instead chose to present at a life sciences conference later in the day.&nbsp;<stembedurl>https://stocktwits.com/TeeMan123/message/613768926</stembedurl><stembedurl>https://stocktwits.com/TeeMan123/message/613804225</stembedurl>Another user noted there was little new information in the earnings release beyond what had already been disclosed on April 25,&nbsp;saying they took advantage of the post-earnings selloff to add shares at a 12% discount.<stembedurl>https://stocktwits.com/Bio_Invest101/message/613802455</stembedurl>Shares of Ironwood have fallen 81.7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Ironwood Pharma Stock Draws Retail Investor Ire With Big Q1 Miss And No Earnings Call

The drugmaker’s first-quarter revenue of $41.1 million came in well below the consensus estimate of $56.7 million, attributed to changes in AbbVie’s gross-to-net rebate reserves. 

Equity

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

IRWD
Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IRWD News

IRWDIronwood Pharmaceuticals Inc - Ordinary Shares - Class A